Basic Information
| LncRNA/CircRNA Name | HOXA-AS3 |
| Synonyms | HOXA6as |
| Region | GRCh38_7:27129977-27155928 |
| Ensemble | ENSG00000254369 |
| Refseq | NR_038831 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot etc. |
| Sample | glioma tissues, cell lines (LN229, U251, SNB19, U87 and H4) |
| Expression Pattern | up-regulated |
| Function Description | It was shown that a novel lncRNA HOXA-AS3 was one of the most significantly upregulated lncRNAs in glioma tissues. Uni and Multivariate Cox regression analysis revealed that HOXA-AS3 was an independent prognostic factor in glioma patients. |
| Pubmed ID | 28881797 |
| Year | 2017 |
| Title | Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma |
External Links
| Links for HOXA-AS3 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |